Javascript must be enabled to continue!
Abstract 178: Desmosome mutations in melanoma promote cellular proliferation and disease progression
View through CrossRef
Abstract
Desmosomes are transmembrane protein complexes that contribute to cell-cell adhesion in the epithelia and other tissues under mechanical stress. Aberrant desmosome expression is often associated with developmental diseases leading to impaired tissue integrity. Recently, similar findings have been reported in cancer; Mutations in desmosomes genes have been observed in various cancer types including skin cancer, head and neck and lung cancer, however mostly epigenetic alterations have been used to associate desmosomes as suppressors of tumor metastasis. Here, we report that desmosomes are frequently mutated in seven cancer types. In melanoma, we find that over 70% of tumors have non-synonymous mutations in desmosomes, and that the desmosome mutational burden is associated with a strong decrease in mRNA expression levels in primary tumor samples (R = -0.23). Differential gene expression analysis and functional characterizations between mutant and wild-type tumors implicates the mutated cells in promoting cell proliferation at early stages of tumorigenesis. These results emerge uniquely from a systems-level analysis integrating multiple proteins in complexes and multiple cell types in heterogeneous tumors.
Citation Format: Maayan Baron, Trey Ideker. Desmosome mutations in melanoma promote cellular proliferation and disease progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 178.
Title: Abstract 178: Desmosome mutations in melanoma promote cellular proliferation and disease progression
Description:
Abstract
Desmosomes are transmembrane protein complexes that contribute to cell-cell adhesion in the epithelia and other tissues under mechanical stress.
Aberrant desmosome expression is often associated with developmental diseases leading to impaired tissue integrity.
Recently, similar findings have been reported in cancer; Mutations in desmosomes genes have been observed in various cancer types including skin cancer, head and neck and lung cancer, however mostly epigenetic alterations have been used to associate desmosomes as suppressors of tumor metastasis.
Here, we report that desmosomes are frequently mutated in seven cancer types.
In melanoma, we find that over 70% of tumors have non-synonymous mutations in desmosomes, and that the desmosome mutational burden is associated with a strong decrease in mRNA expression levels in primary tumor samples (R = -0.
23).
Differential gene expression analysis and functional characterizations between mutant and wild-type tumors implicates the mutated cells in promoting cell proliferation at early stages of tumorigenesis.
These results emerge uniquely from a systems-level analysis integrating multiple proteins in complexes and multiple cell types in heterogeneous tumors.
Citation Format: Maayan Baron, Trey Ideker.
Desmosome mutations in melanoma promote cellular proliferation and disease progression [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21.
Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 178.
Related Results
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract
Background: The etiology of melanoma has generally been thought to be exposure to UV radiation (sun and sun tanning lamps). However, the percent of melanoma...
Divergent pathways of melanoma development: evidence from a Southern European cohort
Divergent pathways of melanoma development: evidence from a Southern European cohort
Nevus counts in the divergent pathway model of melanoma development have been studied mainly in patients in Australia. Our aim was to compare nevus counts and the melanoma subtype ...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Modeling melanoma in reconstructed human skin
Modeling melanoma in reconstructed human skin
With increasing pressure from the European Union to replace, reduce, and refine animal experiments, there is a critical need for models that reliably mimic human diseases in a phys...
Abstract 1627: PHI-501, a novel and potent pan-RAF inhibitor in metastatic melanoma
Abstract 1627: PHI-501, a novel and potent pan-RAF inhibitor in metastatic melanoma
Abstract
Background: PHI-501 has been developed as a novel inhibitor of NRAS mutated acute myeloid leukemia. Big data and artificial intelligence (AI)-based drug dis...
High Resolution Melt Analysis for Rapid and Cost-Effective Screening of TP53 Mutations in Patients with Myeloid Malignancies
High Resolution Melt Analysis for Rapid and Cost-Effective Screening of TP53 Mutations in Patients with Myeloid Malignancies
Abstract
Background
Recent reports have highlighted an adverse impact of TP53 mutations on the prognosis of patients with myeloid malignancies. TP53 m...
Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms
Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms
Abstract
Recurrent somatic mutations of CUX1 are described in myeloid neoplasms. CUX1 is located at chromosome 7q22.1; -7/del(7q) involving CUX1 locus are common abn...
Abstract 3870: Ruxolitinib diminishes cell proliferation and invasiveness in BRAF mutated metastatic melanoma
Abstract 3870: Ruxolitinib diminishes cell proliferation and invasiveness in BRAF mutated metastatic melanoma
Introduction:
Treatment with a BRAF inhibitor of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation has an estimated 5-year survival rate of ...

